EPISODE · Jun 20, 2025 · 5 MIN
Can an oral diabetes drug reduce hepatic scarring from MASH?
from Medical News Podcast · host PeerDirect Publishing
A Chinese trial found dapagliflozin improved MASH outcomes, with higher resolution and fibrosis improvement rates than placebo. A JAMA Network Open survey showed 42% of abortion providers in ban states relocated, mostly to states with protections, highlighting growing care gaps. An oncology study found AI analysis of body composition better predicted chemo dose reductions than body surface area, especially in women.
Embed this episode
NOW PLAYING
Can an oral diabetes drug reduce hepatic scarring from MASH?
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.